Ciprofloxacin inhalation - Aradigm

Drug Profile

Ciprofloxacin inhalation - Aradigm

Alternative Names: ARD-1100; ARD-3100; ARD-3150; CFI; Ciprofloxacin AERx formulation - Aradigm; Ciprofloxacin inhalation modified-release - Aradigm Corporation; Ciprofloxacin inhalation sustained-release - Aradigm; Ciprofloxacin liposomal sustained-release - Aradigm; DRCFI; Dual Release Ciprofloxacin for Inhalation; ILCH; Inhaled liposomal ciprofloxacin hydrochloride; Linhaliq; Lipoquin; Pulmaquin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aradigm Corporation
  • Developer Aradigm Corporation; Oregon State University
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchiectasis; Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Bronchiectasis
  • Preclinical Mycobacterial infections; Pneumonic plague; Q fever; Tularaemia
  • Suspended Cystic fibrosis-associated respiratory tract infections
  • No development reported Acinetobacter infections; Anthrax; Yersinia infections

Most Recent Events

  • 01 Dec 2017 Aradigm Corporation schedules a meeting with the Antimicrobial Drugs Advisory Committee of the US FDA on January 11, 2018 to review the New Drug Application for ciprofloxacin inhalation in non-cystic fibrosis Bronchiectasis (in patients with chronic lung infections with Pseudomonas aeruginosa)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acinetobacter-infections in USA (Inhalation, Liposomal)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anthrax in Canada (Inhalation, Liposomal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top